Answers are grounded in this paper and cite their sources.
Randomized trial assesses efficacy and safety of fluocinolone acetonide in diabetic macular edema, implying reduced treatment burden.
Purpose: NEW DAY was a prospective, randomized, active-controlled, multicenter, phase 4, 18-month study (ClinicalTrials.gov ID NCT04469595). The study assessed the efficacy and safety of the fluocinolone acetonide (FAc; 0.19 mg) intravitreal implant as a baseline therapy in patients with center-involving [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Riemann et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: